The Effect of Acupuncture Treatment on Cognitive Functions and Brain Networks for Long COVID
NCT07355751, Not applicable, Not yet recruiting, Tingting Luo
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effect of Acupuncture Treatment on Cognitive Functions and Brain Networks for Long COVID | ClinicalTrials.gov |
| NCT number | NCT07355751 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 108 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Tingting Luo | ClinicalTrials.gov |
| Conditions | Long Covid | ClinicalTrials.gov |
| Interventions | Acupuncture, Sham acupuncture | ClinicalTrials.gov |
| First posted | 2026-01-21 | ClinicalTrials.gov |
| Last updated | 2026-01-21 | ClinicalTrials.gov |
Registered outcomes 30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change of Addenbrooke's Cognitive Examination-III total score from baseline to the end of 8 weeks | Baseline and 8 weeks | Addenbrooke's Cognitive Examination-III is a cognitive screening tool, and the total score assess general cognitive function. The total score ranges from 0 to 100. Higher score indicates better general cognitive function | ClinicalTrials.gov |
| Primary | Change of Phonemic Fluency Test score from baseline to the end of 8 weeks | Baseline and 8 weeks | Phonemic fluency test measures the number of correct words produced under restricted search conditions of phonemic(letter F) . Higher score indicates better language. | ClinicalTrials.gov |
| Secondary | Changes of Digit Span Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Digit Span Test consists of forward and backward subtests, that respectively assess attention and executive function through measuring the number of correct digit sequences. The minimum score is 0 , and the maximum scores are respectively 10 and 9 for forward and backward subtests. Higher scores indicate better attention and executive function. | ClinicalTrials.gov |
| Secondary | Change of Symbol Digit Modality Test score from baseline to the end of 8 weeks | Baseline and 8 weeks | Symbol Digit Modality Test assesses attention through measuring the number of correct responses within 90 seconds. The minimum score is 0, and the maximum score is 110. Higher score indicates better attention. | ClinicalTrials.gov |
| Secondary | Changes of Trail Making Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Trail Making Test includes Part A(TMT-A) and Part B(TMT-B), that respectively evaluates attention and executive function via measuring the time in seconds required for completing each part of the test. Higher scores indicate worse attention and executive function. | ClinicalTrials.gov |
| Secondary | Changes of Rey Auditory Verbal Learning Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Rey Auditory Verbal Learning Test evaluates different aspects of verbal memory through measuring total learning, repetitions, delayed recall, retroactive interference, and proactive interference. Higher scores for total learning and delayed recall indicate better memory, while higher scores for repetitions, retroactive interference, and proactive interference indicate worse memory. | ClinicalTrials.gov |
| Secondary | Changes of Rey-Osterrieth Complex Figure Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Rey-Osterrieth Complex Figure Test evaluates visuospatial construction ability through measuring the accuracy of copy, and evaluates visual memory via measuring the accuracies of immediate and delayed recalls. Higher scores indicate better visuospatial construction and visual memory. | ClinicalTrials.gov |
| Secondary | Changes of Stroop Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Stroop test consists of Stroop word test(Part A), Stroop color test(Part B) and Stroop color word test(Part C), that assess executive function through measuring the time in second required to complete each part and the number of errors for each part. Higher score for each part indicates worse executive function. | ClinicalTrials.gov |
| Secondary | Change of Category Fluency Test Score from baseline to the end of 8 weeks. | Baseline and 8 weeks | Category Fluency Test assesses language through measuring the number of correct words produced under restricted search condition of category(animals). Higher score for each subtest indicates better language. | ClinicalTrials.gov |
| Secondary | Change of Action Fluency Test Score from baseline to the end of 8 weeks | Baseline and 8 weeks | Action Fluency Test evaluates language via measures the number of correct words produced under restricted search condition of action(kitchen actions). Higher score for each subtest indicates better language | ClinicalTrials.gov |
| Secondary | Change of Boston Naming Test score from baseline to the end of 8 weeks | Baseline and 8 weeks | Boston Naming Test includes 30 items and evaluates language through measuring the total of correct responses. The minimum score is 0, and the maximum score is 30. Higher score indicates better language. | ClinicalTrials.gov |
| Secondary | Change in Fatigue Severity Scale score from baseline to the end of 8 weeks | Baseline and 8 weeks | Fatigue Severity Scale is a self-report questionnaire consisting of 9 items which are devised to evaluate the impact of fatigue on daily functioning, severity of fatigue. The minimum score is 9,and the maximum score is 63. Higher score indicate greater severity of fatigue and impact of fatigue on daily functioning. | ClinicalTrials.gov |
| Secondary | Change of the Generalized Anxiety Disorde-7 score from baseline to the end of 8 weeks | Baseline and 8 weeks | Generalized Anxiety Disorde-7 is a self-report questionnaire with 7 items, that assesses the level of anxiety in the past two week. The minimum score is 0, and the maximum score is 21. Higher score indicates greater severity of anxiety. | ClinicalTrials.gov |
| Secondary | Change of Hamilton Depression Scale score from baseline to the end of 8 weeks | Baseline and 8 weeks | Hamilton Depression Scale is the most commonly used instrument for the assessment of depression in clinical practice. It includes 24 items and assesses the level of depression through measuring factors of Anxiety/Somatization, Weight, Cognitive Impairment, Diurnal Variation, Retardation, Sleep Disturbance, and Hopelessness. The total score range is 0 to 76. Higher total score indicates greater level of depression. | ClinicalTrials.gov |
| Secondary | Change of the MOS Item Short From Health Survey subscores from baseline to the end of 8 weeks | Baseline and 8 weeks | The MOS Item Short From Health Survey is a self-report instrument with 36 items, that assesses quality of life through measuring subscales of Physical Function, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Higher subscores indicate better quality of life. | ClinicalTrials.gov |
| Secondary | Change in clustering coefficient of brain network from baseline to the end of 8 weeks | Baseline and 8 weeks | Clustering coefficient is the average of clustering coefficients across all nodes in a network. Higher value indicates greater density and complexity of the entire network. | ClinicalTrials.gov |
| Secondary | The change in characteristic path length of brain network from baseline to the end of 8 weeks | Baseline and 8 weeks | Characteristic path length the average of shortest path length (the minimum number of edges required to connect one node to another node) across any pair of nodes in the network. Lower value indicates higher speed of information transmission in the network. | ClinicalTrials.gov |
| Secondary | The change in global efficiency of brain network from baseline to the end of 8 weeks | Baseline and 8 weeks | Global efficiency is the mean of inverse of the shortest path length between all pairs of nodes in a network. Higher value reflects better functional integration of the network | ClinicalTrials.gov |
| Secondary | The change in local efficiency of brain network from baseline to the end of 8 weeks. | Baseline and 8 weeks | Local efficiency is the mean of the local efficiency across all nodes in whole network. Higher value suggests greater stability of a local network when the local network is interrupted. | ClinicalTrials.gov |
| Secondary | The change in normalized clustering coefficient from baseline to the end of 8 weeks. | Baseline and 8 weeks | Normalized clustering coefficient is the ratio of culstring coefficient of network to the culstring coefficient of random network. Higher value indicates greater local modularization and specialization. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 42136829 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 9
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Verbal Fluency | Primary outcome | ConductCognition |
| Category Fluency | Secondary outcome | ConductCognition |
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)